Preliminary Results of UCART19, an Allogeneic Anti-CD19 CAR T-Cell Product, in a First-in-Human Trial (CALM) in Adult Patients with CD19+ Relapsed/Refractory B-Cell Acute Lymphoblastic Leukemia (2017)
Attributed to:
Large scale lentiviral vector production
funded by
BBSRC
Abstract
No abstract provided
Bibliographic Information
Digital Object Identifier: http://dx.doi.org/10.1182/blood.v130.suppl_1.887.887
Publication URI: http://dx.doi.org/10.1182/blood.v130.suppl_1.887.887
Type: Journal Article/Review
Parent Publication: Blood
Issue: Suppl_1